27940576|t|Aspirin Suppresses Growth in PI3K - Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling
27940576|a|Despite the high incidence of oncogenic mutations in PIK3CA, the gene encoding the catalytic subunit of PI3K, PI3K inhibitors have yielded little clinical benefit for breast cancer patients. Recent epidemiologic studies have suggested a therapeutic benefit from aspirin intake in cancers harboring oncogenic PIK3CA Here, we show that mutant PIK3CA - expressing breast cancer cells have greater sensitivity to aspirin -mediated growth suppression than their wild-type counterparts. Aspirin decreased viability and anchorage-independent growth of mutant PIK3CA breast cancer cells independently of its effects on COX-2 and NF-κB. We ascribed the effects of aspirin to AMP-activated protein kinase (AMPK) activation, mTORC1 inhibition, and autophagy induction. In vivo, oncogenic PIK3CA -driven mouse mammary tumors treated daily with aspirin resulted in decreased tumor growth kinetics, whereas combination therapy of aspirin and a PI3K inhibitor further attenuated tumor growth. Our study supports the evaluation of aspirin and PI3K pathway inhibitors as a combination therapy for targeting breast cancer. Cancer Res; 77(3); 790-801. ©2016 AACR.
27940576	0	7	Aspirin	T109,T121	C0004057
27940576	8	18	Suppresses	T169	C1260953
27940576	19	25	Growth	T040	C0018270
27940576	29	33	PI3K	T028	C1335212
27940576	36	42	Mutant	T028	C0678941
27940576	43	56	Breast Cancer	T191	C0678222
27940576	60	70	Activating	T045	C0599177
27940576	71	75	AMPK	T116,T126	C2350345
27940576	80	90	Inhibiting	T052	C3463820
27940576	91	97	mTORC1	T116,T123	C2975458
27940576	125	134	incidence	T081	C0021149
27940576	138	147	oncogenic	T028	C0029016
27940576	148	157	mutations	T045	C0026882
27940576	161	167	PIK3CA	T028	C1335212
27940576	173	186	gene encoding	T028	C3839127
27940576	191	208	catalytic subunit	T087	C0600499
27940576	212	216	PI3K	T116,T126	C0044602
27940576	218	222	PI3K	T116,T126	C0044602
27940576	223	233	inhibitors	T121	C0014432
27940576	254	270	clinical benefit	T033	C1333602
27940576	275	288	breast cancer	T191	C0678222
27940576	289	297	patients	T101	C0030705
27940576	299	305	Recent	T079	C0332185
27940576	306	327	epidemiologic studies	T062	C0002783
27940576	333	342	suggested	T078	C1705535
27940576	345	356	therapeutic	T169	C0302350
27940576	357	364	benefit	T081	C0814225
27940576	370	377	aspirin	T109,T121	C0004057
27940576	388	395	cancers	T191	C0006826
27940576	406	422	oncogenic PIK3CA	T116,T126	C0044602
27940576	442	448	mutant	T028	C0678941
27940576	449	455	PIK3CA	T116,T126	C0044602
27940576	458	468	expressing	T045	C0017262
27940576	469	488	breast cancer cells	T025	C1512505
27940576	502	513	sensitivity	T169	C0332324
27940576	517	524	aspirin	T109,T121	C0004057
27940576	535	541	growth	T043	C0007595
27940576	542	553	suppression	T043	C0007613
27940576	565	574	wild-type	T028	C1883559
27940576	589	596	Aspirin	T109,T121	C0004057
27940576	597	606	decreased	T081	C0205216
27940576	607	616	viability	T043	C0007620
27940576	621	649	anchorage-independent growth	T059	C1515979
27940576	653	659	mutant	T028	C0678941
27940576	660	666	PIK3CA	T116,T126	C0044602
27940576	667	686	breast cancer cells	T025	C1512505
27940576	687	700	independently	T033	C1299583
27940576	708	715	effects	T080	C1280500
27940576	719	724	COX-2	T116,T126	C0387583
27940576	729	734	NF-κB	T116,T129	C0079904
27940576	752	762	effects of	T080	C1704420
27940576	763	770	aspirin	T109,T121	C0004057
27940576	774	802	AMP-activated protein kinase	T116,T126	C2350345
27940576	804	808	AMPK	T116,T126	C2350345
27940576	810	820	activation	T045	C0599177
27940576	822	828	mTORC1	T116,T123	C2975459
27940576	829	839	inhibition	T043	C1519312
27940576	845	854	autophagy	T043	C0004391
27940576	875	884	oncogenic	T028	C0029016
27940576	885	891	PIK3CA	T116,T126	C0044602
27940576	900	905	mouse	T015	C0025929
27940576	906	920	mammary tumors	T191	C1458155
27940576	921	928	treated	T169	C1522326
27940576	940	947	aspirin	T109,T121	C0004057
27940576	960	969	decreased	T081	C0205216
27940576	970	982	tumor growth	T191	C0598934
27940576	983	991	kinetics	T070	C0022702
27940576	1001	1012	combination	T080	C0205195
27940576	1013	1020	therapy	T061	C0087111
27940576	1024	1031	aspirin	T109,T121	C0004057
27940576	1038	1042	PI3K	T116,T126	C0044602
27940576	1043	1052	inhibitor	T080	C1999216
27940576	1061	1071	attenuated	T052	C0599946
27940576	1072	1084	tumor growth	T191	C0598934
27940576	1109	1119	evaluation	T058	C0220825
27940576	1123	1130	aspirin	T109,T121	C0004057
27940576	1135	1139	PI3K	T116,T126	C0044602
27940576	1148	1158	inhibitors	T121	C1254351
27940576	1164	1175	combination	T080	C0205195
27940576	1176	1183	therapy	T061	C0087111
27940576	1188	1197	targeting	T169	C1521840
27940576	1198	1211	breast cancer	T191	C0678222